Vericiguat | List of Frontiers open access articles

Brief Research Report

Published on 26 Aug 2025

Eligible patients with heart failure prescribed vs. not prescribed vericiguat in the United States

in Heart Failure and Transplantation

Stephen J. Greene
Catelyn R. Coyle
Lucy N. Hancock
Kathryn W. Tebbs
Sophie G. Barlow
Andra S. Stevenson
Engels N. Obi

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2025.1633435

2,809 views

Original Research

Published on 11 Oct 2024

Vericiguat combined with “new quadruple” therapy enhances cardiac function and life quality in patients with heart failure: a single-center prospective study

in General Cardiovascular Medicine

Di Zhao
Yanjuan Zhang
Yonghong Yong
Liansheng Wang
Jiabao Liu

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2024.1476976

5,611 views
4 citations

Original Research

Published on 27 Jan 2026

Vericiguat attenuates cyclosporine A-induced nephropathy by targeting the NF-κB/TGF-β1 axis: an integrated network pharmacology, Mendelian randomization, and experimental study

in Inflammation

XuanKe Liu
MengJie Tang
JiaYing Lu
YiJing Kong
WenXuan Shen
ChunJiang Zhang
XiaoPing Yang

Frontiers in Immunology

doi 10.3389/fimmu.2025.1756582

678 views

Review

Published on 06 Nov 2025

Effectiveness and safety of vericiguat in patients with heart failure and reduced ejection fraction: a narrative review of real-world evidence studies

in Heart Failure and Transplantation

Carlos Escobar
Pedro Caravaca-Pérez
Jose Maria Fernandez Rodriguez
Ines Gomez-Otero
Ainara Lozano-Bahamonde
Alejandro I. Pérez-Cabeza
José Pérez-Silvestre
Carles Rafols
Alberto Esteban-Fernández

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2025.1644646

2,358 views

Review

Published on 08 Mar 2024

Vericiguat in patients with heart failure across the spectrum of left ventricular ejection fraction: a patient-level, pooled meta-analysis of VITALITY-HFpEF and VICTORIA

in Cardiovascular Endocrinology

Chao Chen
Jin Lv
Changzhao Liu

Frontiers in Endocrinology

doi 10.3389/fendo.2024.1335531

6,932 views
7 citations

Review

Published on 05 Sep 2022

Cost effectiveness analyses of pharmacological treatments in heart failure

in Drugs Outcomes Research and Policies

Audrey Huili Lim
Nusaibah Abdul Rahim
Jinxin Zhao
S. Y. Amy Cheung
Yu-Wei Lin

Frontiers in Pharmacology

doi 10.3389/fphar.2022.919974

18,834 views
13 citations

Original Research

Published on 04 Mar 2025

Short-term outpatient follow-up of vericiguat treatment in patients hospitalized for heart failure

in Heart Failure and Transplantation

Zihan Li
Tingting Li
Tingxun Liu
Yuanqiao Liu
Daoyuan Si
Yuquan He
Ping Yang

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2025.1465700

3,130 views

Brief Research Report

Published on 06 Jan 2025

Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial

in Heart Failure and Transplantation

Alberto Esteban-Fernández
Alejandro Recio-Mayoral
Raquel López-Vilella
Gregorio de Lara
Moisés Barrantes-Castillo
Inés Gómez-Otero
Julio Nuñez-Villota
Carolina Robles-Gamboa
José López-Aguilera
Ángel Iniesta-Manjavacas

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2024.1504427

3,670 views
2 citations

Systematic Review

Published on 06 Feb 2026

Differential cardiovascular benefits of SGLT2 inhibitors, sacubitril/valsartan, omecamtiv mecarbil, and vericiguat across heart failure phenotypes: a systematic review and meta-analysis

in Drugs Outcomes Research and Policies

Meng Wang
Zhihong Zuo
Ting Wu
Zijing Zhou

Frontiers in Pharmacology

doi 10.3389/fphar.2026.1644757

617 views

Original Research

Published on 01 Sep 2025

Initiation of vericiguat and short-term cardiovascular function improvement in heart failure patients with and without worsened renal function

in General Cardiovascular Medicine

Xinyu Zhang
Wei Zhou
Hui Liu
Chengquan Zhang
Yifan Qi
Xiao Yuan
Zuyi Yuan
Lizhe Sun
Jianqing She
Bowen Lou

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2025.1628411

2,495 views
3 citations

Original Research

Published on 19 Jan 2023

Stimulation of soluble guanylate cyclase by vericiguat reduces skeletal muscle atrophy of mice following chemotherapy

in Pharmacology of Anti-Cancer Drugs

Bo-ang Hu
Yu-lin Li
Hai-tao Han
Bin Lu
Xu Jia
Lu Han
Wei-xuan Ma
Ping Zhu
Zhi-hao Wang
Wei Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1112123

5,683 views
5 citations

Systematic Review

Published on 10 Jun 2025

Analysis of research trends and development prospects of soluble guanylate cyclase stimulators/activators: using bibliometric methods

in Experimental Pharmacology and Drug Discovery

Bing Ju Yan
Jing Zhang
Jun Wang
Hong Xia Yuan

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1501330

3,575 views

Systematic Review

Published on 24 Nov 2021

Comparison of Pharmacological Treatment Effects on Long-Time Outcomes in Heart Failure With Preserved Ejection Fraction: A Network Meta-analysis of Randomized Controlled Trials

in Drugs Outcomes Research and Policies

Yaowang Lin
Meishan Wu
Bihong Liao
Xinli Pang
Qiuling Chen
Jie Yuan
Shaohong Dong

Frontiers in Pharmacology

doi 10.3389/fphar.2021.707777

7,630 views
10 citations

Articles

Eligible patients with heart failure prescribed vs. not prescribed vericiguat in the United States

Vericiguat combined with “new quadruple” therapy enhances cardiac function and life quality in patients with heart failure: a single-center prospective study

Vericiguat attenuates cyclosporine A-induced nephropathy by targeting the NF-κB/TGF-β1 axis: an integrated network pharmacology, Mendelian randomization, and experimental study

Effectiveness and safety of vericiguat in patients with heart failure and reduced ejection fraction: a narrative review of real-world evidence studies

Vericiguat in patients with heart failure across the spectrum of left ventricular ejection fraction: a patient-level, pooled meta-analysis of VITALITY-HFpEF and VICTORIA

Cost effectiveness analyses of pharmacological treatments in heart failure

Short-term outpatient follow-up of vericiguat treatment in patients hospitalized for heart failure

Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial

Differential cardiovascular benefits of SGLT2 inhibitors, sacubitril/valsartan, omecamtiv mecarbil, and vericiguat across heart failure phenotypes: a systematic review and meta-analysis

Initiation of vericiguat and short-term cardiovascular function improvement in heart failure patients with and without worsened renal function

Stimulation of soluble guanylate cyclase by vericiguat reduces skeletal muscle atrophy of mice following chemotherapy

Analysis of research trends and development prospects of soluble guanylate cyclase stimulators/activators: using bibliometric methods

Comparison of Pharmacological Treatment Effects on Long-Time Outcomes in Heart Failure With Preserved Ejection Fraction: A Network Meta-analysis of Randomized Controlled Trials